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Restless Legs SyndromeRestless legs syndrome is a curious neurological disorder of unknown
aetiology. A new study has found that Drosophilamutants in the fly homologue
of a human gene, BTBD9, that has been implicated as a risk factor for restless
legs display important features of the syndrome.Paul J. Shaw1
and Stephen P. Duntley2
Restless legs syndrome is a common
neurological disorder characterized by
an urge to move the legs associated
with uncomfortable sensations that
occur or worsen with rest, are relieved
by movements, and are worse in the
evening [1]. Motor restlessness is
evident when awake and periodic limb
movements frequently occur during
sleep, resulting in sleep fragmentation
and non-restorative sleep. When the
syndrome is mild it may be a mere
nuisance, but when severe it can be
life-altering, resulting in profound
sleep disruption, impaired daytime
functioning, a global decrease in
quality of life and possibly increased
cardiovascular disease risk [2].
The diagnosis is made by clinical
symptoms and there is no definitive
confirmatory testing available.
Although clinical research has
demonstrated that restless legssyndrome is associated with iron
deficiency [3] and can be treated
pharmacologically with dopamine
agonists [4], the underlying
mechanisms are largely unknown
and even localization of the primary
pathology within the nervous system
is uncertain. Population and family
studies indicate that restless legs
syndrome has a strong genetic
component, so several groups have
carried out genome-wide association
studies to identify genes that confer
susceptibility to restless legs
syndrome [5]. These studies have
successfully identified a number of
genetic variants suspected to be
involved in restless legs syndrome,
including one named BTBD9 [6,7].
While additional loci continue to be
identified [8], it has been difficult to
demonstrate that these susceptibility
genes are causative for restless legs
syndrome. In this issue of Current
Biology, Freeman et al. [9] report how
they used the molecular genetictools available in the model genetic
organism Drosophila melanogaster
to functionally characterize the fly
homologue of BTBD9 (dBTBD9) as
a causal factor in restless legs
syndrome.
BTBD9 is a poorly characterized
gene that accounts for approximately
50% of the population attributable risk
for restless legs syndrome and is
therefore an ideal candidate for
functional analysis using Drosophila
genetics. To begin, Freeman et al. [9]
identified the fly homologue of BTBD9
and created two null mutations in the
gene. When they examined sleep in
these mutants, they found that both
mutant alleles caused severely
fragmented nighttime sleep and an
increase in the amount of waking after
sleep onset, as is seen in human
patients with restless legs syndrome.
Because sleep fragmentation is only
one component of restless legs
syndrome, the authors needed to
evaluate aspects of movement that
have face-validity with symptoms seen
in human patients with restless legs
syndrome. In humans, the diagnosis of
restless legs syndrome is facilitated by
the ‘suggested immobilization test’, in
which periodic limb movements and
leg discomfort are worsened when
subjects are asked to sit in bed with
their legs outstretched for an hour [10].
Intriguingly, when mutants in dBTBD9
were confined to a small space, to
simulate the suggested immobilization
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locomoter behavior than controls.
Moreover, when locomotor behavior
was precisely quantified in an
independent assay, the mutants were
found to spend more time in longer
uninterrupted bouts of walking than
controls. Together, these data indicate
that dBTB9 mutant flies recapitulate
key behavioral aspects of restless
legs syndrome, including sleep
fragmentation and motor restlessness.
To determine whether dBTB9 would
also show physiological changes found
in restless legs syndrome patients,
Freeman et al. [9] examined dopamine
signaling and iron homeostasis in the
mutant flies. Interestingly, they found
that flies mutant for dBTBD9 show
dramatically reduced brain dopamine
levels and that the abnormal sleep
phenotype was completely rescued
by administering mutant flies the
dopamine D2 receptor agonist
Pramipexole, which is used clinically
in humans to treat restless legs
syndrome. Importantly, Freeman et al.
[9] used RNA interference (RNAi) to
show that they could recapitulate
restless legs syndrome symptoms by
knocking-down dBTBD9 expression
in a subset of dopaminergic neurons.
Finally, the authors over-expressed
BTBD9 in HEK cells to confirm that the
gene does indeed play a role in iron
homeostasis, acting via regulation of
iron regulatory protein-2 (IRP2). It is
worth noting that a homologue of
another restless legs syndrome
associated variant, MEIS1, has also
been shown to affect iron homeostasis
in Caenorhabditis elegans [11].
How doesBTBD9 regulate dopamine
signalling, iron homeostasis and sleep?
Although much more work needs to be
done, Freeman et al. [9] propose that
the BTBD9 protein belongs to a family
of BTB-domain containing substrate
adaptors for the Cullin-3 (Cul3) class
of E3 ubiquitin ligases. Interestingly,
Cul3 has recently been shown to
regulate sleep in flies [12], further
supporting the idea that Cul3 has a role
in sleep regulation. In the case of iron
homeostasis, BTBD9 may act together
with Cullin-3 to regulate levels of iron
regulatory protein-2 (IRP2), which
controls ferritin expression and thus
iron metabolism. BTBD9 also seems
to play a role in dopamine biosynthesis
by unknown mechanisms. Several
questions remain but they are now
experimentally tractable. Are iron
regulation and dopamine regulationmechanistically related, or are they
independent processes? Is the
specificity of dBTBD9 within
dopaminergic neurons due to
restricted expression of dBTBD9 in a
defined set of dopaminergic neurons?
Or, is the specificity of dBTBD9 due to
differences in the presence of Cul3
substrates in particular neurons? Is the
ability of dBTBD9 to influence sleep
regulation confined to dopaminergic
neurons or does dBTBD9 play a more
fundamental role in regulating sleep
and waking throughout the nervous
system? Finally, which are the
substrates for BTBD9 and Cul3, and
how might they influence restless legs
syndrome?
Genome-wide association studies
have succeeded in identifying a large
number of disease susceptibility
genes. Nonetheless, it is frequently
difficult to collect additional data that
can provide causative or functional
insight into the underlying molecular
mechanisms and this is only
complicated further when evaluating
complex traits that are differentially
influenced by environmental
conditions. With this in mind, one of
the most compelling aspects of the
approach of Freeman et al. [9] is
the successful use of a model system
to functionally characterize a
susceptibility gene that was originally
identified in human genome-wide
association studies. A similar strategy
has recently been used to functionally
examine genes identified in
a genome-wide association study
for loci influencing the burden of
Alzheimer’s disease [13] and to extend
the results from a small genetic study
on short sleeping humans [14]. In this
regard, it is important to note that
tools have been developed so that
orthologous genes can be quickly
identified in Drosophila and other
model organisms [15]. These tools will
certainly expedite the ability of labs to
identify and then test candidate genes
from genome-wide association studies
to provide critical insight into
mechanism and causation of human
disease states. Thus, the use of model
systems to functionally characterize
genes identified with genome-wide
association studies is a move in the
right direction.References
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